Search

Displaying results 2581 - 2590 of 10000 in total
  1. Indication

    Moderate Chronic Hand Eczema (CHE)

    go.drugbank.com/conditions/DBCOND0169739
    Drugs: Delgocitinib
    Synonyms: Moderate Chronic Hand Eczema (CHE)
  2. Drug

    Regadenoson

    go.drugbank.com/drugs/DB06213
    ApprovedInvestigational

    Manufactured by Astellas and FDA approved April 10, 2008.

  3. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    The NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636] … [A18696] In 2016, it was granted approval to treat primary biliary cholangitis in combination with [ursodeoxycholic acid], which was previously the mainstay treatment for this condition.

  4. Drug

    Regdanvimab

    go.drugbank.com/drugs/DB16405
    ApprovedWithdrawn

    Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020. … [A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130]

  5. Drug

    Sonrotoclax

    go.drugbank.com/drugs/DB18753
    ApprovedInvestigational

    It promotes tumor cell survival by sequestering proapoptotic proteins and blocking the intrinsic mitochondrial apoptotic pathway. … It is the first BCL-2 inhibitor approved for MCL and the second oncology-approved BCL-2 inhibitor overall, following venetoclax.

  6. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk … neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

  7. Drug

    Serplulimab

    go.drugbank.com/drugs/DB17451
    ApprovedInvestigational

    Most recently, it was approved in the EU in February 2025 for the treatment of extensive-stage small cell lung cancer.[L52968,L52953] … It was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries.

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
  8. Target

    20-ketosteroid reductase (20-hydroxysteroid dehydrogenase)

    go.drugbank.com/bio_entities/BE0009795
    EnzymeHumans and other mammals

    Inactivates 3alpha-hydroxy-5alpha-pregnan-20-one (3alpha,5alpha-THP) into less potent neurosteroid 3alpha,20alpha-dihydroxy-5alpha-pregnane (PubMed:11995921, PubMed:12604236). … Catalyzes the inactivation of 5alpha-DHT and progesterone converting them into 3alpha/beta-androstanediols and (20S)-hydroxypregn-4-en-3-one, respectively (PubMed:10998348, PubMed:24434280).

    Synonyms: CHDR, 20-alpha-HSDFunction: 17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase [NAD(P)+] activity
  9. Drug

    Inositol nicotinate

    go.drugbank.com/drugs/DB08949
    ApprovedWithdrawn

    It is used in food supplements as a source of niacin (vitamin B3), where hydrolysis of 1 g (1.23 mmol) inositol hexanicotinate yields 0.91 g nicotinic acid and 0.22 g inositol. … It is associated with reduced flushing compared to other vasodilators by being broken down into the metabolites and inositol at a slower rate.

    Mixtures: Inositol Nicotinate 250 mg, Inositol Nicotinate 250 mg
  10. Drug

    Merbromin

    go.drugbank.com/drugs/DB13392
    Investigational

    It is an organomercuric disodium salt compound and a fluorescein that is available in many countries, except Switzerland, France, Germany, and the United States where the drug was withdrawn from market

    Products: BERKOMER SOLUSYON, 50 ML